Overview
McDermott Will & Emery has advised the biotechnology company Innate Pharma on a capital increase reserved for the Institute for Follicular Lymphoma Innovation (IFLI).
This agreement aims to explore the clinical potential of IPH6501, Innate’s anti-CD20 ANKET® in follicular lymphoma.
The McDermott team involved in this transaction was made up of partners Anne-France Moreau and Emmanuelle Trombe.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
